Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Debt (2016 - 2025)

Northwest Biotherapeutics' Total Debt history spans 16 years, with the latest figure at $21.7 million for Q4 2025.

  • Quarterly results put Total Debt at $21.7 million for Q4 2025, up 48.81% from a year ago — trailing twelve months through Dec 2025 was $21.7 million (up 48.81% YoY), and the annual figure for FY2025 was $21.7 million, up 48.81%.
  • Total Debt for Q4 2025 was $21.7 million at Northwest Biotherapeutics, up from $16.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $358.6 million in Q1 2021 to a low of $8.1 million in Q1 2025.
  • The 5-year median for Total Debt is $21.5 million (2023), against an average of $82.6 million.
  • The sharpest move saw Total Debt skyrocketed 3127.05% in 2021, then plummeted 95.27% in 2022.
  • Year by year, Total Debt stood at $131.9 million in 2021, then tumbled by 34.4% to $86.6 million in 2022, then plummeted by 75.44% to $21.3 million in 2023, then tumbled by 31.24% to $14.6 million in 2024, then soared by 48.81% to $21.7 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $21.7 million, $16.9 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.